

Cost-effective Method to Quickly Produce and Purify Large Quantities of Biologically Active ncRNAs

Tech ID: 24318 / UC Case 2014-279-0

CONTACT

Victor Haroldsen

haroldsen@ucdavis.edu

tel: 530-752-7717.



INVENTORS

- ▶ Chen, Qiuxia
- ▶ Li, Meimei
- ▶ Wang, Weipeng
- ▶ Yu, Aiming

OTHER INFORMATION

KEYWORDS

Biomarkers, Chimeric

RNA, E. coli, RNA

delivery, RNA production,

RNA purification,

Therapeutics

CATEGORIZED AS


- ▶ **Biotechnology**
 - ▶ Genomics
 - ▶ Health
 - ▶ Other
- ▶ **Materials & Chemicals**
 - ▶ Biological
- ▶ **Medical**
 - ▶ Delivery Systems
 - ▶ Diagnostics

ABSTRACT

Researchers at the University of California, Davis have developed a method to develop and purify large quantities of ncRNA for basic and translational research, as well as for therapeutics delivery.

FULL DESCRIPTION

The discovery of the role of chimeric, non-coding, RNAs (ncRNA) in the control of various cellular processes has greatly expanded researchers’ understanding of cellular genetics. Advances include insights into developing novel therapeutic strategies. As one example, tumor-suppressive ncRNAs that are depleted in carcinoma tissues may be reintroduced into cancer cells to manage tumor progression. Unfortunately, existing methods of ncRNA production - such as chemical synthesis - are very expensive and run the risk of altering the RNA’s structure and its associated biological activity. The lack of an efficient method for producing large quantities of inexpensive, naturally-occurring and biologically-functional ncRNA agents hinders basic research on ncRNA structures. It also limits potentially critical, translational research on ncRNA-based therapies.



Researchers at the University of California, Davis have developed a method to cost-effectively design, produce, and purify large amounts of chimeric, non-coding, RNA agents using recombinant RNA technology. This method involves using E.coli and tRNA scaffolding. This production approach allows for high levels of ncRNA expression and stability in a recombinant host cell. The resulting ncRNA can be purified with high homogeneity, and used to help control biological processes. The ncRNA can also become a “stealth” carrier for the delivery of therapeutic RNA agents or RNA biomarkers.

APPLICATIONS

- Increases availability of ncRNA for basic and translational research
- Potential carrier of biomarkers or therapeutics

FEATURES/BENEFITS

- Provides a source of inexpensive, high-purity, ncRNA
- Increases opportunities for the delivery of therapeutic or biomarkers using stealth RNA

carriers

- [Gene Therapy](#)
- [Research Tools](#)
- [Therapeutics](#)
- **[Research Tools](#)**
- [Nucleic Acids/DNA/RNA](#)

RELATED CASES

2014-279-0

PATENT STATUS

Country	Type	Number	Dated	Case
United States Of America	Issued Patent	10,619,156	04/14/2020	2014-279

ADDITIONAL TECHNOLOGIES BY THESE INVENTORS

- ▶ [New label-free method for direct RNase activity detection in biological samples](#)
- ▶ [Bioengineered RNA Molecules for Cancer Therapy](#)

University of California, Davis	Tel:	© 2014 - 2020, The Regents of the University of
Technology Transfer Office	530.754.8649	California
1 Shields Avenue, Mrak Hall 4th Floor,	techtransfer@ucdavis.edu	Terms of use
Davis,CA 95616	https://research.ucdavis.edu/technology-transfer/	Privacy Notice
	Fax:	
	530.754.7620	